Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer
June 26 2014 - 9:43AM
Marketwired
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for
the Prognosis and Treatment of Prostate Cancer
PRINCETON, NJ and REHOVOT, ISRAEL--(Marketwired - Jun 26, 2014)
- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and
provider of microRNA-based molecular diagnostics and therapeutics,
announces receipt of a Notice of Allowance from the United States
Patent and Trademark Office (USPTO) for U.S. Patent
Application No. 13/390,995, entitled "Compositions and Methods for
Prognosis and Treatment of Prostate Cancer." The patent claims
cover the expression of miR-205 as an indicator of good prognosis
and relates to methods and kits for prognosis of prostate
cancer.
Prostate cancer typically is first suspected by elevated levels
of serum Prostate Specific Antigen (PSA). However, PSA levels are
often elevated for reasons unrelated to prostate cancer. Although
an elevated PSA level often leads to biopsy, about 80% of all
prostate biopsies are either negative or indicate a low likelihood
of high-grade cancer. Further complicating prostate cancer
diagnosis and treatment is the difficulty in determining which
cancers are low-risk and which are high-risk.
"The biomarker we have identified could be used for predicting
the aggressiveness of prostate tumors and for determining the most
appropriate course of treatment," stated Kenneth A. Berlin,
President and Chief Executive Officer of Rosetta Genomics. "In
addition, this biomarker, over-expressed in primary prostate tumors
could be used as a therapeutic target for prostate cancer. Rosetta
Genomics continues to fortify its intellectual property portfolio
to protect and broaden our leading position in microRNA
technology. We look forward to monetizing this new piece of
intellectual property."
Rosetta's robust patent portfolio includes 35 issued patents,
including 31 in the U.S. In addition, Rosetta has 47 patent
applications pending, of which 25 are in the U.S.
About Prostate Cancer Prostate cancer is the most common
non-cutaneous cancer in males, with 1 of every 7 men being
diagnosed during his lifetime, and is the second most common cause
of cancer-related death in men in the United States. The American
Cancer Society estimates that in 2014 about 233,000 new cases of
prostate cancer will be diagnosed and about 29,480 men will die of
prostate cancer.
About Rosetta Genomics Founded in 2000, Rosetta's integrative
research platform combining bioinformatics and state-of- the-art
laboratory processes has led to the discovery of hundreds of
biologically validated novel human microRNAs. Building on its
strong patent position and proprietary platform technologies,
Rosetta is working on the application of these technologies in the
development and commercialization of a full range of microRNA-based
diagnostic tools and therapeutics. Rosetta currently commercializes
a full range of microRNA-based molecular diagnostics. Rosetta's
cancer testing services are commercially available through its
Philadelphia-based CAP-accredited, CLIA-certified lab. For more
information please visit www.rosettagenomics.com.
Forward-Looking Statement Disclaimer Various statements in this
release concerning Rosetta's future expectations, plans and
prospects, including without limitation, Rosetta's Cancer of Origin
Test™, Rosetta's development or commercialization of molecular
diagnostics, prognostic or therapeutic services or tool, the
timeline for the development of Rosetta's potential molecular
diagnostic or prognostic assays or therapeutics, and specifically
its development of a diagnostic or prognostic assays or
therapeutics,, the market acceptance of Rosetta's cancer testing
services, particularly the Rosetta Cancer Origin Test™, Rosetta
monetizing its intellectual property in any way and Rosetta's
development of personalized medicine products and services,
constitute forward-looking statements for the purposes of the safe
harbor provisions under The Private Securities Litigation Reform
Act of 1995. Actual results may differ materially from those
indicated by these forward-looking statements as a result of
various important factors, including those risks more fully
discussed in the "Risk Factors" section of Rosetta's Annual Report
on Form 20-F for the year ended December 31, 2012 as filed with the
SEC. In addition, any forward-looking statements represent
Rosetta's views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
Rosetta Genomics Contact: Rosetta Genomics Ken Berlin President
& CEO 609-419-9003 investors@rosettagenomics.com Investor
Contacts: LHA Anne Marie Fields 212-838-3777 afields@lhai.com or
Bruce Voss 310-691-7100 bvoss@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2024 to May 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From May 2023 to May 2024